Absea is a fast-growing biotechnology company that has been revolutionizing the protein engineering industry since 2020. Its proprietary platform enables the development of up to 1,000 soluble proteins and monoclonal antibodies per month. With a library of 14,000 proteins covering 65% of the human proteome, the synthetic proteome portfolio is continuously expanding. The company supports AI-driven protein design, diagnostics, and drug development. Absea aims to be a long-term partner for leading laboratories, companies, and service providers.